In his new role with the FDA, Dr. Vinay Prasad will oversee the regulation of costly drugs, including vaccines, gene ...

Vinay Prasad has worked as a professor of medicine ... He steps into the shoes vacated by Peter Marks, who resigned from the role a few weeks ago – reportedly before being pushed out ...

The United States Food and Drug Administration has chosen Dr Vinay Prasad to lead its Center for Biologics Evaluation and Research.

We want you to take advantage of everything Cancer Therapy Advisor has to offer. To view unlimited content, log in or register for free.

CBER’s new chief has argued for more stringent measures of assessing drugs for cancer and rare diseases, suggesting he might ...

Dr Vinay Prasad, an oncologist and outspoken critic of the FDA leadership and COVID-19 mandates has been named as the new ...

The FDA's decision to appoint Vinay Prasad, MD, MPH, to head its Center for Biologics Evaluation and Research (CBER) raised ...

The appointment, announced May 6 by FDA Commissioner Dr. Marty Makary, places Prasad at the helm of one of the agency’s most ...

Prasad has questioned COVID-19 recommendations ... He takes over from Dr Peter Marks, who led the division for 13 years and played a major role in the COVID vaccine rollout. Marks resigned in ...

Dr. Vinay Prasad, a prominent critic of the pharmaceutical industry and the FDA, has been named to oversee the agency’s ...

His new role has caused biotech stocks to drop more than 5% WEDNESDAY, May 7, 2025 (HealthDay News) — The U.S. Food and Drug Administration (FDA) has chosen Dr. Vinay Prasad, a professor at the ...